Insights+: The US FDA New Drug Approvals in June 2023

Shots:The US FDA approved 12 NDAs and 3 BLA in June 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 69 novel products in 2023In June 2023, the major highlights drugs were Talzenna + Xtandi approval for prostate cancer, Rystiggo for generalized myasthenia gravisPharmaShots…

BySenior EditorJuly 19, 2023

INSIGHTS+

PharmaShots’ Key Highlights of Second Quarter 2023

Shots:The second quarter of 2023 highlights multiple clinical trial results, approvals, and numerous deals. There are major alliances in this quarter which include Merck acquired Prometheus for ~$10.8B and Astellas entered into a definitive agreement to acquire Iveric Bio for ~$5.9BThe second quarter of the year also showcases multiple approvals of the therapies…

BySenior EditorJuly 3, 2023

Insights+: The US FDA New Drug Approvals in June 2023

PharmaShots’ Key Highlights of Second Quarter 2023

Contact US

OUR INFORMATION

FOLLOW US